Follow the KAMADA LTD stock price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €474.8m. The latest transaction was reported on 8 September 2026 (Levée d'options). Among the most active insiders: Brenner Yael. All data is free.
12
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate KAMADA LTD Strong Buy (bullish), based on 4 analysts. Average price target: US$13.50.
18Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 8,846 of 29,064 companies
61.3
score / 100
Value
55
Quality
68
FCF yld3.3%
Earn yld4.3%
EV/EBITDA12.4x
ROE8.4%
Gross mgn42%
Net mgn11%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
2,776 shares@ US$8.5827.6% of flowOrdinary SharesSEC:0001213900-26-095332:1
12 of 12 declarations
About KAMADA LTD
Kamada Ltd is a biopharmaceutical company focused on the development and commercialization of therapeutic products based on proteins. It is listed on NASDAQ.